TNFRSF9 and neoplasm: Intratumoral and systemic administration of 4-1BBL and IL-12 showed similar effects (105, 131, 182), and, in fact, intratumoral 4-1BBL may induce a more robust secondary tumor response than systemic 4-1BB antibodies (131).